Preventive effects of astaxanthin on diethylnitrosamine-induced liver tumorigenesis in C57/BL/KsJ-db/db obese mice

Hepatology Research

Volumn 46, Issue 3, 2016, Pages E201-E209

  Ohno, Tomohiko ^a   Shimizu, Masahito ^a   Shirakami, Yohei ^a   Miyazaki, Tsuneyuki ^a   Ideta, Takayasu ^a   Kochi, Takahiro ^a   Kubota, Masaya ^a   Sakai, Hiroyasu ^a   Tanaka, Takuji ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Astaxanthin; Liver tumorigenesis; Obesity; Oxidative stress

Indexed keywords

ADIPONECTIN; ASTAXANTHIN; BIOLOGICAL MARKER; CYCLIN D1; DIETHYLNITROSAMINE; GLUTATHIONE PEROXIDASE 1; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; LIVER; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WHITE ADIPOSE TISSUE;

EID: 84961912447     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12550     Document Type: Article

References (44)

1. Kochi T, Shimizu M, Terakura D et al. Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett 2014 (Jan 1); 342: 60-9.
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003 (Apr 24); 348: 1625-38.
3. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006 (Mar); 4: 369-80.
4. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009 (Dec 15); 115: 5651-61.
5. Shimizu M, Tanaka T, Moriwaki H. Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol 2013 (Mar); 35: 191-202.
6. Shimizu M, Kubota M, Tanaka T, Moriwaki H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci 2012; 13: 579-95.
7. Shimizu M, Yasuda Y, Sakai H et al. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 2011 (Jun 28); 11: 281.
8. Ambati RR, Phang SM, Ravi S, Aswathanarayana RG. Astaxanthin: sources, extraction, stability, biological activities and its commercial applications--a review. Mar Drugs 2014 (Jan); 12: 128-52.
9. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr Metab (Lond) 2010; 7: 18.
10. Choi HD, Youn YK, Shin WG. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects. Plant Foods Hum Nutr 2011 (Nov); 66: 363-9.
11. McCarty MF. Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. Med Hypotheses 2011 (Oct); 77: 550-6.
12. Tanaka T, Shnimizu M, Moriwaki H. Cancer chemoprevention by carotenoids. Molecules 2012; 17: 3202-42.
13. Yasui Y, Hosokawa M, Mikami N, Miyashita K, Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem Biol Interact 2011 (Aug 15); 193: 79-87.
14. Shimizu M, Sakai H, Shirakami Y et al. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-+(db)/+Lepr(db) mice. Cancer Prev Res (Phila) 2011 (Jan); 4: 128-36.
15. Shimizu M, Sakai H, Shirakami Y et al. Preventive Effects of (-)-Epigallocatechin Gallate on Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BL/KsJ-db/db Mice. Cancer Prev Res (Phila) 2011 (Mar); 4: 396-403.
16. Terakura D, Shimizu M, Iwasa J et al. Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Carcinogenesis 2012 (Dec); 33: 2499-506.
17. Nagano J, Shimizu M, Hara T et al. Effects of indoleamine 2, 3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. PLoS One 2013; 8: e73404.
18. Iwasa J, Shimizu M, Shiraki M et al. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci 2010 (Feb); 101: 460-7.
19. Bhalla K, Hwang BJ, Dewi RE et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012 (Apr); 5: 544-52.
20. Shirakami Y, Gottesman ME, Blaner WS. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis 2012 (Feb); 33: 268-74.
21. Suzuki Y, Imai K, Takai K et al. Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test. J Cancer Res Clin Oncol 2013 (May); 139: 845-52.
22. Tripathi DN, Jena GB. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. Mutat Res 2010 (Feb); 696: 69-80.
23. Hussein G, Nakagawa T, Goto H et al. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci 2007 (Jan 16); 80: 522-9.
24. Yoshida H, Yanai H, Ito K et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 2010 (Apr); 209: 520-3.
25. Kamada Y, Matsumoto H, Tamura S et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 2007 (Oct); 47: 556-64.
26. Fukushima H, Miwa Y, Shiraki M et al. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatol Res 2007 (Sep); 37: 765-70.
27. Saxena NK, Fu PP, Nagalingam A et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010 (Nov); 139: 1762-73, 73 e1-5.
28. Yasuda Y, Shimizu M, Shirakami Y et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010 (Jul); 101: 1701-7.
29. Kubota M, Shimizu M, Sakai H et al. Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice. Nutr Cancer 2012; 64: 72-9.
30. Villanueva EC, Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Int J Obes (Lond) 2008 (Dec); 32 (Suppl 7): S8-12.
31. Akasaka Y, Tsunoda M, Ogata T, Ide T, Murakami K. Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor. Biochim Biophys Acta 2010 (Oct); 1801: 1115-22.
32. Liu ZJ, Bian J, Liu J, Endoh A. Obesity reduced the gene expressions of leptin receptors in hypothalamus and liver. Horm Metab Res 2007 (Jul); 39: 489-94.
33. Sahai A, Malladi P, Pan X et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004 (Nov); 287: G1035-43.
34. Arunkumar E, Bhuvaneswari S, Anuradha CV. An intervention study in obese mice with astaxanthin, a marine carotenoid--effects on insulin signaling and pro-inflammatory cytokines. Food Funct 2012 (Feb); 3: 120-6.
35. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 (Jun); 41: 1313-21.
36. Naugler WE, Sakurai T, Kim S et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007 (Jul 6); 317: 121-4.
37. Zein CO, Lopez R, Fu X et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012 (Oct); 56: 1291-9.
38. Zein CO, Yerian LM, Gogate P et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011 (Nov); 54: 1610-9.
39. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008 (Feb); 18: 54-61.
40. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007 (Oct); 7: 763-77.
41. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008 (Dec); 34: 643-8.
42. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci: a journal and virtual library 1998 (Feb 15); 3: d250-68.
43. Kato J. Induction of S phase by G1 regulatory factors. Front Biosci: a journal and virtual library 1999 (Dec 1); 4: D787-92.
44. Zhang X, Zhao WE, Hu L, Zhao L, Huang J. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells. Arch Biochem Biophys 2011 (Aug 1); 512: 96-106.